VFA
AMLX icon

Valeo Financial Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Valeo Financial Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
10,045
+45
+0.5% +$696 ﹤0.01% 776
2026
Q1 		$139K Sell
10,000
-5,000
-33% -$70.3K ﹤0.01% 707
2025
Q4 		$181K Buy
15,000
+5,000
+50% +$67.9K ﹤0.01% 765
2025
Q3 		$136K Hold
10,000
– – ﹤0.01% 782
2025
Q2 		$64.1K Hold
10,000
– – ﹤0.01% 750
2025
Q1 		$35.4K Buy
+10,000
New +$35.6K ﹤0.01% 678

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Valeo Financial Advisors's AMLX Position: Q2 2026 in Review

Valeo Financial Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 0.45% in Q2 2026, buying an estimated $696 and bringing the position to 10,045 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #776.

Valeo Financial Advisors first reported a position in AMLX in Q1 2025 and has held it in 6 quarters since. The position peaked at $181K in Q4 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Valeo Financial Advisors held 10,045 shares of Amylyx Pharmaceuticals worth $180K as of Q2 2026.
  • Valeo Financial Advisors bought 45 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $696.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Valeo Financial Advisors's portfolio in Q2 2026, its #776 holding.
  • Valeo Financial Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Valeo Financial Advisors's Amylyx Pharmaceuticals position peaked at $181K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Valeo Financial Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.